Drug Information

Drug (ID: DG01363) and It's Reported Resistant Information

• Name: Durvalumab
• Indication:
  In total 7 Indication(s)
  Biliary tract cancer [ICD-11: 2C15]; Approved; [1]
  Diffuse large B-cell lymphoma [ICD-11: 2A81]; Approved; [1]
  Hepatocellular carcinoma [ICD-11: 2C12]; Approved; [1]
  Melanoma [ICD-11: 2C30]; Approved; [1]
  Pancreatic ductal carcinoma [ICD-11: 2C10]; Approved; [1]
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Approved; [1]
  Ureteral cancer [ICD-11: 2C92]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Lung cancer [ICD-11: 2C25]; [1]
• Target: Programmed cell death 1 ligand 1 (PD-L1); PD1L1_HUMAN; [1]
• TTD Drug ID: D0LS9E
• DrugBank ID: DB11714

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Serine/threonine-protein kinase STK11 (STK11) [1]

• Molecule Alteration: Mutation; .
• Resistant Disease: Non-small cell lung cancer [ICD-11: 2C25.Y]
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• In Vitro Model: 4T1-Luc2 cells; Mammary gland; Mus musculus (Mouse); CVCL_A4BM
• In Vitro Model: CD138+ myeloma cells; Pleural effusion; Homo sapiens (Human); N.A.
• In Vitro Model: HTH7 cells; Thyroid gland; Homo sapiens (Human); CVCL_6289
• In Vitro Model: EMT6 WT cells; Breast; Mus musculus (Mouse); CVCL_1923
• In Vivo Model: Mouse tumor model; Mus musculus
• Experiment for Drug Resistance: Flow cytometry
• Mechanism Description: Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.

References

• Ref 1: Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown .Cancer Discov. 2021 Nov;11(11):2828-2845. doi: 10.1158/2159-8290.CD-20-1543. Epub 2021 Jul 6. 10.1158/2159-8290.CD-20-1543